Prabhoo Ram, Chaddha Ram, Iyer Rajagopalan, Mehra Apurv, Ahdal Jaishid, Jain Rishi
Department of Orthopedic Surgery, Mukund Hospital Mumbai, Maharashtra.
Department of Orthopedic and Spine Surgery, Apollo Hospitals, Navi Mumbai, Maharashtra.
Orthop Rev (Pavia). 2019 Jun 20;11(2):8070. doi: 10.4081/or.2019.8070. eCollection 2019 May 23.
is the most common pathogen causing bone and joint infections (BJI). In India, prevalence of Methicillin resistant (MRSA) is increasing at an alarming rate and emerged as an important contributor towards the difficult to treat BJI. Currently available anti-MRSA agents have their own limitations with regards to reduced susceptibility as well as safety and tolerability. Furthermore, biofilms over the prosthesis with invariably multi-drug resistant strains leads to complex treatment processes. This necessitates the need to develop and screen new antibiotics against MRSA that can easily penetrate the deep pockets of infection and take care of the challenges discussed. This review aims to discuss on MRSA infection in bone and joint infection, current antibiotic regimen, its associated limitations, and finally, the need to develop new antibiotic therapy for effective management of patients with BJI.
是引起骨与关节感染（BJI）最常见的病原体。在印度，耐甲氧西林金黄色葡萄球菌（MRSA）的患病率正以惊人的速度上升，并成为难以治疗的BJI的一个重要因素。目前可用的抗MRSA药物在敏感性降低以及安全性和耐受性方面都有其自身的局限性。此外，假体上的生物膜与始终存在的多重耐药菌株导致治疗过程复杂。这就需要开发和筛选针对MRSA的新抗生素，这些抗生素能够轻易穿透感染的深部病灶，并应对所讨论的挑战。本综述旨在讨论骨与关节感染中的MRSA感染、当前的抗生素治疗方案、其相关局限性，以及最后，开发新的抗生素疗法以有效管理BJI患者的必要性。
